ProPhase Labs Balance Sheet Health
Financial Health criteria checks 3/6
ProPhase Labs has a total shareholder equity of $49.4M and total debt of $10.3M, which brings its debt-to-equity ratio to 20.8%. Its total assets and total liabilities are $91.9M and $42.5M respectively.
Key information
20.8%
Debt to equity ratio
US$10.26m
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.74m |
| Equity | US$49.38m |
| Total liabilities | US$42.54m |
| Total assets | US$91.93m |
Recent financial health updates
Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11
ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30Recent updates
Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?
Mar 04ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry
Jan 09ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 08ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
Oct 20Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Jul 22ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
Jun 28Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More
May 14ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing
May 06A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Apr 12ProPhase Labs opens Covid testing facility in New York
Jan 29ProPhase Labs announces $5.5M registered direct offering of common stock and warrants
Jan 05ProPhase Labs expands COVID-19 testing capacity in New York, shares +21%
Dec 09Financial Position Analysis
Short Term Liabilities: PRPH's short term assets ($47.6M) exceed its short term liabilities ($20.9M).
Long Term Liabilities: PRPH's short term assets ($47.6M) exceed its long term liabilities ($21.7M).
Debt to Equity History and Analysis
Debt Level: PRPH's net debt to equity ratio (11.2%) is considered satisfactory.
Reducing Debt: PRPH's debt to equity ratio has increased from 0% to 20.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if PRPH has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PRPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.